hotspot -WSS

hotspot

author：leisure time 2025-10-01 21:40:28 - browse：427

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

hotspot

WSS

Flagship Pioneering startup Sonata Therapeutics lays off 21

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Secretariat’s lessons for human medicine

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

Ukraine seeks to reclaim its role as a hub for clinical trials

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

A new drug could help frostbite victims avoid its ravages

Hepatitis C has a cure — but many Americans still lack access to it

Neutralizing antibodies against HIV shows promise in children

Drug repurposing or repositioning? The language matters

Trump seeks lengthy delay of classified docs trial, citing upcoming election

State Dept. review finds Biden bears some blame for Afghanistan failures

What to know about a major upcoming Wegovy heart health study

United colonoscopy coverage change 'may cost lives,' doctors say

Secretariat’s lessons for human medicine

explore

The PBM ad wars are taking over Washington, D.C.

US intelligence assessment says Iran not currently developing nuclear weapons

Researchers tackle phage therapy hurdles for wider adoption

Another man arrested in connection with shooting at Kansas nightclub

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Weight loss drugs aren’t covered by Obamacare. That may change

leisure time

Wikipedia

hotspot

Wikipedia